A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2011
10/13/2011	WO2011127101A1 Sophorolipid analog compositions
10/13/2011	WO2011127088A2 Methods and compositions for decreasing chronic pain
10/13/2011	WO2011127070A2 IRE-1α INHIBITORS
10/13/2011	WO2011127058A2 Biomarkers for mdm2 inhibitors for use in treating disease
10/13/2011	WO2011127051A1 Modulators of the gpr119 receptor and the treatment of disorders related thereto
10/13/2011	WO2011127048A2 NON-HORMONAL STEROID MODULATORS OF NF-ĸB FOR TREATMENT OF DISEASE
10/13/2011	WO2011127019A2 Methods for treating respiratory viral infection
10/13/2011	WO2011126998A1 Treatment of ataxia telangiectasia
10/13/2011	WO2011126974A1 Novel single chemical entities and methods for delivery of oligonucleotides
10/13/2011	WO2011126969A1 Prodrugs of an hiv reverse transcriptase inhibitor
10/13/2011	WO2011126960A1 Oxazole derivatives useful as modulators of faah
10/13/2011	WO2011126910A2 Compositions and methods for the treatment of somatosensory disorders
10/13/2011	WO2011126903A2 Multisubstituted aromatic compounds as inhibitors of thrombin
10/13/2011	WO2011126853A2 Prevention or delay of onset of oral mucositis
10/13/2011	WO2011126852A2 Treatment of gout
10/13/2011	WO2011126821A2 Indolyl or indolinyl hydroxamate compounds
10/13/2011	WO2011126810A2 Intravaginal drug delivery device
10/13/2011	WO2011126733A2 Combination therapies: inhibitors of gaba transaminase and nkcc1
10/13/2011	WO2011126673A1 Cell reservoirs created by polymer plugs
10/13/2011	WO2011126409A1 Telomerase inhibitors and a method for the preparation thereof
10/13/2011	WO2011126401A1 1,3-dialkyl-benzimidazole halogenides as agents for treating multiple sclerosis
10/13/2011	WO2011126352A2 Anti-tuberculosis preparation based on an inclusion complex of cyclodextrin with rifampicin and a method for the preparation thereof
10/13/2011	WO2011126327A2 Pharmaceutical composition with controlled-release properties comprising mosapride or levodropropizine, and preparing method thereof
10/13/2011	WO2011126324A2 Pomegranate extract having a high ellagic acid content, and use of the pomegranate extract
10/13/2011	WO2011126099A1 Prophylactic agent or therapeutic agent for diabetes or obesity
10/13/2011	WO2011126071A1 Agent for inhibiting viral infection and/or treating infectious disease, and method for inhibiting viral infection and/or treating infectious disease
10/13/2011	WO2011125967A1 Cephem compound having catechol group
10/13/2011	WO2011125966A1 Cephem compound having pseudo-catechol group
10/13/2011	WO2011125943A1 Modified oligonucleotide
10/13/2011	WO2011125930A1 Prophylactic or therapeutic agent for inflammatory bowel diseases or autoimmune peripheral neuropathy
10/13/2011	WO2011125916A1 Composition for amelioration of hypoalbuminemia
10/13/2011	WO2011125911A1 Metal complexes and anticancer agents comprising same as active ingredient
10/13/2011	WO2011125838A1 Therapeutic agent or preventive agent for urine collection disorder
10/13/2011	WO2011125836A1 Therapeutic agent or prophylactic agent for fibromyalgia
10/13/2011	WO2011125763A1 Preventive and/or remedy for hand and foot syndrome
10/13/2011	WO2011125500A1 Process for producing granules of fine particles containing sparingly water-soluble drug
10/13/2011	WO2011125331A1 Metal salen complex derivative and process for production thereof
10/13/2011	WO2011125245A1 Method for prediction of prognosis of small cell lung cancer, method for treatment of small cell lung cancer, method for amelioration of prognosis of small cell lung cancer, and method for screening for therapeutic agent for small cell lung cancer, each utilizing mirna
10/13/2011	WO2011125075A2 A novel gastroretentive delivery of macrolide
10/13/2011	WO2011125062A1 Process for the preparation of memantine hydrochloride
10/13/2011	WO2011125057A1 Cosmetic composition
10/13/2011	WO2011125011A1 Novel hypoglycemic compounds
10/13/2011	WO2011124992A1 Substantially pure strontium ranelate
10/13/2011	WO2011124973A1 Excipient from trigonella foenum-graceum seeds and process for preparation thereof
10/13/2011	WO2011124953A2 Controlled release pharmaceutical compositions of tapentadol
10/13/2011	WO2011124930A1 P38 map kinase inhibitors
10/13/2011	WO2011124923A2 Novel compounds
10/13/2011	WO2011124895A2 Phospholipid-containing pharmaceutical and nutraceutical compositions
10/13/2011	WO2011124713A1 Labelled huprine derivatives and their use in medical imaging
10/13/2011	WO2011124712A1 7,11-methanocycloocta [b] quinoline derivative as highly functionalizable acetylcholinesterase inhibitors
10/13/2011	WO2011124697A1 Antimicrobial compounds of 1,4- naphtoquinone structure
10/13/2011	WO2011124655A1 Improved process for preparing valsartan
10/13/2011	WO2011124638A1 Pimobendan manufacturing process
10/13/2011	WO2011124580A1 Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
10/13/2011	WO2011124571A1 Pharmaceutical compositions highly dosed with biotin
10/13/2011	WO2011124570A2 Oral film formulation
10/13/2011	WO2011124525A1 Combinations of medicaments, containing pde4 inhibitors and ep4 receptor antagonists
10/13/2011	WO2011124524A1 Combinations of medicaments, containing pde4 inhibitors and ep4 receptor antagonists
10/13/2011	WO2011124430A1 Tricyclic indazole compound, method of preparation and pharmaceutical composition containing it
10/13/2011	WO2011124381A1 Fillers comprising gellan or pectin beads
10/13/2011	WO2011124366A1 Piroxicam for prophylactically and therapeutically treating herpes infections
10/13/2011	WO2011124249A1 1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)-3-pyridinyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid salts
10/13/2011	WO2011124124A1 Prasugrel hydrochloride acetic acid solvate and its crystalline, preparation method thereof
10/13/2011	WO2011124093A1 Bicyclic quinolone compounds, preparation methods and uses thereof
10/13/2011	WO2011124087A1 Oxadiazole-based piperazine derivatives and applications thereof
10/13/2011	WO2011124031A1 Polypeptide conjugate of paclitaxel or docetaxel
10/13/2011	WO2011123946A1 Kinase inhibitors and method of treating cancer with same
10/13/2011	WO2011123945A1 Compostions, methods and uses for treating respiratory syncytial virus infection
10/13/2011	WO2011123942A1 Fatty acid derivatives of catechins and methods of their use
10/13/2011	WO2011123937A1 Kinase inhibitors and method of treating cancer with same
10/13/2011	WO2011123911A1 Antitumoral compounds of testosterone and chemotherapeutic drugs
10/13/2011	WO2011123890A1 Radioprotector compounds and methods
10/13/2011	WO2011091142A3 Crystalline and amorphous forms of olanzapine pamoate
10/13/2011	WO2011087857A3 Compositions and methods for treating obesity and diabetes
10/13/2011	WO2011086412A3 Imidazolone-chalcone derivatives as potential anticancer agent and process for the preparation thereof
10/13/2011	WO2011083114A3 Serine hydrolase formulation
10/13/2011	WO2011082266A3 Substituted heterocyclic compounds
10/13/2011	WO2011079343A3 Substituted pyridines and pyrimidines for the production of cardiomyocyte - like cells
10/13/2011	WO2011072216A9 Treatment methods utilizing stem cell mobilizers and immunosuppressive agents
10/13/2011	WO2011071995A9 Compounds and methods of treating ocular disorders
10/13/2011	WO2011071981A3 Anti-cytomegalovirus activity of artemisinin-derived dimers
10/13/2011	WO2011070444A3 Compositions for use in methods of treating friedreich's ataxia
10/13/2011	WO2011069487A3 Dna aptamers that specifically bind to the soluble interleukin-6 receptor
10/13/2011	WO2011069149A3 Cathepsin s inhibitors
10/13/2011	WO2011068927A3 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF
10/13/2011	WO2011068786A9 Treating xerophthalmia with compounds increasing meibomian gland secretion
10/13/2011	WO2011068546A3 Prognosis, diagnosis and identification of multiple myeloma based on global gene expression profiling
10/13/2011	WO2011067758A3 Immunogenic fragments and multimers from streptococcus pneumoniae proteins
10/13/2011	WO2011067236A3 Raltegravir polymorphs
10/13/2011	WO2011066484A9 Isoxazoline compounds in type 2 diabetes and other maladies
10/13/2011	WO2011066379A3 METHOD OF REDUCING INTRATUMORAL pHe AND ACID-MEDIATED INVASION
10/13/2011	WO2011062864A3 Inhibitors of nox enzymes and methods of use thereof
10/13/2011	WO2011060408A3 2'-fluoro-6'-methylene carbocyclic nucleosides and methods of treating viral infections
10/13/2011	WO2011059609A9 Dendrimer compositions and methods of synthesis
10/13/2011	WO2011059586A3 Multifunctional small molecules
10/13/2011	WO2011050947A3 Tape, in particular, adhesive tape, for the treatment of skin disorders comprising at least one hyperkeratosis inhibitor and/or at least one keratinolytic agent
10/13/2011	WO2011049344A3 Method of preparing sitagliptin and intermediates used therein
10/13/2011	WO2011049332A3 2,7-substituted thieno[3,2-d]pyrimidine compounds as protein kinase inhibitors
10/13/2011	WO2011047794A3 Medical utility of glycan-binding proteins and glycans
10/13/2011	WO2011044207A3 Compositions containing a high concentration of polar sphingolipid(s)

1 ... 1522 1523 1524 1525 1526 1527 1528 1529 1530 1531 1532 1533 1534 1535 1536 1537 1538 1539 1540 1541 1542 ... 7860